VENTURA, FULVIO
VENTURA, FULVIO
Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: data from the Brisighella Heart Study
2020 Arrigo F G Cicero , Federica Fogacci , Giuliano Tocci , Fulvio Ventura , Vivianne Presta , Elisa Grandi , Elisabetta Rizzoli , Sergio D'Addato , Claudio Borghi , Brisighella Heart Study group
Current pharmacotherapeutic options for primary dyslipidemia in adults
2019 Cicero AFG, Landolfo M, Ventura F, Borghi C
Diabetes in the third millennium: Prognosis improves, but juvenile forms are more frequent.
2019 Ventura F.; Borghi C.
Evaluation of twelve formulas for LDL-C estimation in a large, blinded, random Italian population.
2021 Piani F, Cicero AFG, Ventura F, Dormi A, Fogacci F, Patrono D, Mancini R, Ramazzotti E, Borghi C, D'Addato S; BLIP Study Group.
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up
2022 Cicero A.F.G.; Fogacci F.; Rizzoli E.; Giovannini M.; D'Addato S.; Borghi C.; Grandi E.; Ventura F.; Coppola P.; Ianniello E.; Soldati M.; Piani F.; Iamino I.R.; Palmisano S.; Landolfo M.; Bacchelli S.
Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study
2022 Cicero AFG, Fogacci F, Derosa G, D'Angelo A, Ventura F, Rizzoli E, D'Addato S, Borghi C, On Behalf Of The Brisighella Heart Study Group
Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation
2018 Cicero, Arrigo F G; Fogacci, Federica; Bove, Marilisa; Ventura, Fulvio; Giovannini, Marina; Borghi, Claudio
Who Needs Acetylsalicylic Acid? Some Order After Many Studies
2020 Claudio Borghi; Fulvio Ventura